{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '33']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT>3xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', \"Hy's Law\", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', \"Reportas an SAE if possible Hy's Law case: ALT23xULNand Bilirubin>2xULN (>35% direct) or\", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', \"Once the QT correction formula has been chosen for a participant's eligibility,\", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '34']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', '35']\n\n###\n\n", "completion": "END"}